Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Capsid Assembly Modulator ALG-001075 Prevents CCCDNA Formation and HBV DNA Integration in Vitro

Tuesday, April 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the efficacy of Capsid Assembly Modulator ALG-001075 in preventing CCCDNA formation and HBV DNA integration in vitro. This development could represent a significant advancement in the treatment of chronic HBV infection. The findings suggest that ALG-001075 may play a crucial role in future therapeutic strategies against HBV.
Price reaction · baseline $6.32 (2026-04-28T17:13:00.000Z) · hit during market hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-001075 effectively prevents CCCDNA formation.
  • The compound shows promise in inhibiting HBV DNA integration.
  • Potential for significant impact on chronic HBV infection treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-001075?

ALG-001075 is a Capsid Assembly Modulator targeting HBV.

How does ALG-001075 work?

It prevents CCCDNA formation and HBV DNA integration in vitro.

What is the significance of this research?

It could lead to new treatment strategies for chronic HBV infection.

Is ALG-001075 effective against HBV?

Yes, it shows promising results in inhibiting HBV-related processes.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-001075 HBV chronic infection capsid assembly modulator DNA integration
Last updated: Apr 28, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →